Developments in the management of Chagas cardiomyopathy

Herbert B. Tanowitz, Fabiana S. Machado, David C. Spray, Joel M. Friedman, Oren S. Weiss, Jose N. Lora, Jyothi Nagajyothi, Diego N. Moraes, Nisha Garg, Maria Carmo P Nunes, Antonio Luiz P Ribeiro

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Over 100 years have elapsed since the discovery of Chagas disease and there is still much to learn regarding pathogenesis and treatment. Although there are antiparasitic drugs available, such as benznidazole and nifurtimox, they are not totally reliable and often toxic. A recently released negative clinical trial with benznidazole in patients with chronic Chagas cardiomyopathy further reinforces the concerns regarding its effectiveness. New drugs and new delivery systems, including those based on nanotechnology, are being sought. Although vaccine development is still in its infancy, the reality of a therapeutic vaccine remains a challenge. New ECG methods may help to recognize patients prone to developing malignant ventricular arrhythmias. The management of heart failure, stroke and arrhythmias also remains a challenge. Although animal experiments have suggested that stem cell based therapy may be therapeutic in the management of heart failure in Chagas cardiomyopathy, clinical trials have not been promising.

Original languageEnglish (US)
Pages (from-to)1393-1409
Number of pages17
JournalExpert Review of Cardiovascular Therapy
Volume13
Issue number12
DOIs
StatePublished - Dec 2 2015

Fingerprint

Chagas Cardiomyopathy
Cardiac Arrhythmias
Nifurtimox
Vaccines
Heart Failure
Clinical Trials
Antiparasitic Agents
Nanotechnology
Chagas Disease
Poisons
Drug Delivery Systems
Cell- and Tissue-Based Therapy
Electrocardiography
Stem Cells
Therapeutics
Stroke
benzonidazole

Keywords

  • Arrhythmias
  • Chagas cardiomyopathy
  • Chagas disease
  • Heart failure
  • Myocardial fibrosis
  • Nanotechnology
  • Oxidative stress
  • Stem cell therapy
  • Vaccine development

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Internal Medicine

Cite this

Tanowitz, H. B., Machado, F. S., Spray, D. C., Friedman, J. M., Weiss, O. S., Lora, J. N., ... Ribeiro, A. L. P. (2015). Developments in the management of Chagas cardiomyopathy. Expert Review of Cardiovascular Therapy, 13(12), 1393-1409. https://doi.org/10.1586/14779072.2015.1103648

Developments in the management of Chagas cardiomyopathy. / Tanowitz, Herbert B.; Machado, Fabiana S.; Spray, David C.; Friedman, Joel M.; Weiss, Oren S.; Lora, Jose N.; Nagajyothi, Jyothi; Moraes, Diego N.; Garg, Nisha; Nunes, Maria Carmo P; Ribeiro, Antonio Luiz P.

In: Expert Review of Cardiovascular Therapy, Vol. 13, No. 12, 02.12.2015, p. 1393-1409.

Research output: Contribution to journalArticle

Tanowitz, HB, Machado, FS, Spray, DC, Friedman, JM, Weiss, OS, Lora, JN, Nagajyothi, J, Moraes, DN, Garg, N, Nunes, MCP & Ribeiro, ALP 2015, 'Developments in the management of Chagas cardiomyopathy', Expert Review of Cardiovascular Therapy, vol. 13, no. 12, pp. 1393-1409. https://doi.org/10.1586/14779072.2015.1103648
Tanowitz HB, Machado FS, Spray DC, Friedman JM, Weiss OS, Lora JN et al. Developments in the management of Chagas cardiomyopathy. Expert Review of Cardiovascular Therapy. 2015 Dec 2;13(12):1393-1409. https://doi.org/10.1586/14779072.2015.1103648
Tanowitz, Herbert B. ; Machado, Fabiana S. ; Spray, David C. ; Friedman, Joel M. ; Weiss, Oren S. ; Lora, Jose N. ; Nagajyothi, Jyothi ; Moraes, Diego N. ; Garg, Nisha ; Nunes, Maria Carmo P ; Ribeiro, Antonio Luiz P. / Developments in the management of Chagas cardiomyopathy. In: Expert Review of Cardiovascular Therapy. 2015 ; Vol. 13, No. 12. pp. 1393-1409.
@article{418b69aada6f4bbaabd974a1043867c8,
title = "Developments in the management of Chagas cardiomyopathy",
abstract = "Over 100 years have elapsed since the discovery of Chagas disease and there is still much to learn regarding pathogenesis and treatment. Although there are antiparasitic drugs available, such as benznidazole and nifurtimox, they are not totally reliable and often toxic. A recently released negative clinical trial with benznidazole in patients with chronic Chagas cardiomyopathy further reinforces the concerns regarding its effectiveness. New drugs and new delivery systems, including those based on nanotechnology, are being sought. Although vaccine development is still in its infancy, the reality of a therapeutic vaccine remains a challenge. New ECG methods may help to recognize patients prone to developing malignant ventricular arrhythmias. The management of heart failure, stroke and arrhythmias also remains a challenge. Although animal experiments have suggested that stem cell based therapy may be therapeutic in the management of heart failure in Chagas cardiomyopathy, clinical trials have not been promising.",
keywords = "Arrhythmias, Chagas cardiomyopathy, Chagas disease, Heart failure, Myocardial fibrosis, Nanotechnology, Oxidative stress, Stem cell therapy, Vaccine development",
author = "Tanowitz, {Herbert B.} and Machado, {Fabiana S.} and Spray, {David C.} and Friedman, {Joel M.} and Weiss, {Oren S.} and Lora, {Jose N.} and Jyothi Nagajyothi and Moraes, {Diego N.} and Nisha Garg and Nunes, {Maria Carmo P} and Ribeiro, {Antonio Luiz P}",
year = "2015",
month = "12",
day = "2",
doi = "10.1586/14779072.2015.1103648",
language = "English (US)",
volume = "13",
pages = "1393--1409",
journal = "Expert Review of Cardiovascular Therapy",
issn = "1477-9072",
publisher = "Expert Reviews Ltd.",
number = "12",

}

TY - JOUR

T1 - Developments in the management of Chagas cardiomyopathy

AU - Tanowitz, Herbert B.

AU - Machado, Fabiana S.

AU - Spray, David C.

AU - Friedman, Joel M.

AU - Weiss, Oren S.

AU - Lora, Jose N.

AU - Nagajyothi, Jyothi

AU - Moraes, Diego N.

AU - Garg, Nisha

AU - Nunes, Maria Carmo P

AU - Ribeiro, Antonio Luiz P

PY - 2015/12/2

Y1 - 2015/12/2

N2 - Over 100 years have elapsed since the discovery of Chagas disease and there is still much to learn regarding pathogenesis and treatment. Although there are antiparasitic drugs available, such as benznidazole and nifurtimox, they are not totally reliable and often toxic. A recently released negative clinical trial with benznidazole in patients with chronic Chagas cardiomyopathy further reinforces the concerns regarding its effectiveness. New drugs and new delivery systems, including those based on nanotechnology, are being sought. Although vaccine development is still in its infancy, the reality of a therapeutic vaccine remains a challenge. New ECG methods may help to recognize patients prone to developing malignant ventricular arrhythmias. The management of heart failure, stroke and arrhythmias also remains a challenge. Although animal experiments have suggested that stem cell based therapy may be therapeutic in the management of heart failure in Chagas cardiomyopathy, clinical trials have not been promising.

AB - Over 100 years have elapsed since the discovery of Chagas disease and there is still much to learn regarding pathogenesis and treatment. Although there are antiparasitic drugs available, such as benznidazole and nifurtimox, they are not totally reliable and often toxic. A recently released negative clinical trial with benznidazole in patients with chronic Chagas cardiomyopathy further reinforces the concerns regarding its effectiveness. New drugs and new delivery systems, including those based on nanotechnology, are being sought. Although vaccine development is still in its infancy, the reality of a therapeutic vaccine remains a challenge. New ECG methods may help to recognize patients prone to developing malignant ventricular arrhythmias. The management of heart failure, stroke and arrhythmias also remains a challenge. Although animal experiments have suggested that stem cell based therapy may be therapeutic in the management of heart failure in Chagas cardiomyopathy, clinical trials have not been promising.

KW - Arrhythmias

KW - Chagas cardiomyopathy

KW - Chagas disease

KW - Heart failure

KW - Myocardial fibrosis

KW - Nanotechnology

KW - Oxidative stress

KW - Stem cell therapy

KW - Vaccine development

UR - http://www.scopus.com/inward/record.url?scp=84948578179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948578179&partnerID=8YFLogxK

U2 - 10.1586/14779072.2015.1103648

DO - 10.1586/14779072.2015.1103648

M3 - Article

VL - 13

SP - 1393

EP - 1409

JO - Expert Review of Cardiovascular Therapy

JF - Expert Review of Cardiovascular Therapy

SN - 1477-9072

IS - 12

ER -